Analgesic Allergies Linked to Pregnancy Risks
A study found that maternal nonnarcotic analgesic allergy labels (NNAALs) are associated with increased risks for eclampsia and preterm birth. Infants born to mothers with NNAALs also faced higher risks for neonatal opioid withdrawal syndrome and longer hospital stays. The findings suggest that proactive evaluations for patients with NNAALs could improve perinatal outcomes.
- ▪Maternal NNAALs were linked to a more than 60% higher risk for eclampsia and a nearly 20% higher risk for preterm birth.
- ▪Infants born to individuals with NNAALs had a nearly 50% higher risk for neonatal opioid withdrawal syndrome.
- ▪The study analyzed over 2.2 million singleton live births in California from 2016 to 2021.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Maternal nonnarcotic analgesic allergy labels (NNAALs) were linked to a more than 60% higher risk for eclampsia and a nearly 20% higher risk for preterm birth. Infants born to individuals with NNAALs faced a nearly 50% higher risk for neonatal opioid withdrawal syndrome and longer hospital stays.METHODOLOGY:Researchers conducted a retrospective analysis using the Study of Outcomes in Mothers and Infants, a population-based cohort of all births in California between 2016 and 2021, with a total of 2,244,210 singleton live births with linked maternal-fetal records included in the analysis.Maternal NNAALs were identified using International Classification of Diseases, 10th Revision (ICD-10) code Z88.6 from hospital discharge, emergency department, and ambulatory surgery records for…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
